WATERTOWN, Mass., April 28 /PRNewswire-FirstCall/ -- V.I. Technologies,
Inc. (Nasdaq: VITX) ("Vitex" or "the Company"), a biotechnology company
dedicated to developing the next generation of anti-infective therapeutics,
has been invited to speak at the Rodman & Renshaw Techvest 2nd Annual Global
Healthcare Conference, to be held at The InterContinental Hotel in Paris,
France on Thursday, May 5, 2005. Vitex's presentation is scheduled to begin
that day at 10:30 a.m., Central European Summer Time, or 4:30 a.m., U.S.
Eastern Daylight Time. Dr. Samuel K. Ackerman, Chairman and CEO of Vitex,
will present.
A link to the live audiocast of Vitex's presentation will be available on
the Company's Web site at http://www.vitechnologies.com. The audiocast link
to access a replay of the presentation will be archived and available through
Thursday, May 12, 2005.
About Vitex
Vitex is developing the next generation of anti-infective products. The
Company is engaged in the discovery and development of small molecule oral
drugs for the treatment of HIV and other major human viral diseases. Vitex's
proprietary discovery technologies and lead therapeutic candidate PA-457 focus
on novel targets in the virus life cycle, including virus fusion and virus
maturation. The Company's separate INACTINE(TM) technology is designed to
inactivate a wide range of viruses, bacteria and parasites in blood products,
and has demonstrated its ability to remove prion proteins. For more
information on Vitex, please visit our web site at:
http://www.vitechnologies.com.
Except for the historical information contained herein, the matters
discussed are forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. These
statements involve risks and uncertainties, such as the Company's ability to
execute plans to resume its clinical trial program for its lead product
candidate, the INACTINE(TM) viral inactivation system for red blood cells, the
execution of the Company's financing plans, anticipated future clinical trial
timelines or results, the timely availability of new products, market
acceptance of the Company's products, the impacts of competitive products and
pricing, government regulation of the Company's products, the Company's
ability to complete product development collaborations and other strategic
transactions and other risks and uncertainties set forth in the Company's
filings with the Securities and Exchange Commission. These risks and
uncertainties could cause actual results to differ materially from any
forward-looking statements made herein.
CONTACT:
John R. Barr
President
617-926-1551
john.barr@vitechnologies.com
SOURCE V.I. Technologies, Inc.
 back to top
Related links:
http://www.vitechnologies.com
CONTACT:
John R. Barr, President of V.I. Technologies,
+1-617-926-1551, john.barr@vitechnologies.com
|
